NCT01025232View on ClinicalTrials.gov

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Age Related Macular DegenerationChoroidal Neovascular MembraneSubfoveal Neovascular Age-Related Macular DegenerationMacular DegenerationWet Age-Related Macular Degeneration
Interventions
DRUG

Ranibizumab

Intravitreal Injection of 2.0mg formulation

Trial Locations (2)

77030

Greater Houston Retina Research, Houston

77384

Greater Houston Retina Research, The Woodlands

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

David M. Brown, M.D.

OTHER